Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Todd Neale

October 02, 2024

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

Todd Neale

November 20, 2023

News Daily News

FDA Approves First Extravascular ICD

Yael L. Maxwell

October 23, 2023

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

L.A. McKeown

August 23, 2022

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

FDA Grants HeartWare LVAD a Destination Therapy Indication

Todd Neale

September 28, 2017

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Majority of FDA Advisors Give Green Light to Amplatzer PFO Closure Device for Stroke

Shelley Wood

May 25, 2016

Advertisement

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

FDA Approves First Extravascular ICD

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Roughly 80% of ESC Guideline Writers Have Financial COIs

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Funding the Future: How Industry Support for CV Trials Could Evolve

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

FDA Grants HeartWare LVAD a Destination Therapy Indication

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Majority of FDA Advisors Give Green Light to Amplatzer PFO Closure Device for Stroke

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content